Wire · opportunities
Experimental Pan-KRAS Pill Plus Cetuximab Shrank Tumors in 5 of 16 Advanced Colorectal ...
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 22 November 2026 · Fusion42 review
An experimental pan-KRAS inhibitor pill, ALTA3263, combined with cetuximab, showed tumor shrinkage in 31% of advanced colorectal cancer patients in an early Phase 1 trial, addressing multiple KRAS mutations beyond the limited G12C target of existing drugs.
This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.
◆ ◆ The Wire takeaway
You now have a new drug in testing that could open colorectal cancer patients with hard-to-treat KRAS mutations. Testing combinations beyond G12C mutations can shift treatment options in a tough biotech niche.
◆ Coverage
1 source · 21 Nov 2026
◆ Related on Wire
◆ Topics